Electrical active implants that overwrite natural sensor signals in the human body might offer alternative treatment options to established pharmaceutical therapies. "Electroceutical", "electronic pills" and "bioelectronics medicine" are synonyms for approaches that have been driven since 2013 by GlaxoSmithKline and several research groups in the USA. The scientific community that uses neuronal interfaces and implants is growing fast. Widespread diseases in ageing societies like diabetes, rheumatic arthritis, asthma but also hypertension, autoimmune diseases like Crohn's disease are on the agenda of research groups as well as enterprises. BrainLinks-BrainTools member Thomas Stieglitz has presented the topic with its new promises and challenges on the microTEC Süedwest Cluster conference 2018 in Freiburg as well as in the latest issue of the VDE HEALTH expert reports (01-2018).